Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The combination of olmesartan medoxomil and hydrochlorothiazide (HCTZ) [olmesartan medoxomil/HCTZ] has previously been shown to produce significantly greater SBP/DBP reductions than monotherapy with either agent alone in a randomized, double-blind, factorial study in patients with stage 2 hypertension. Compared with the evaluation of a single mean BP reduction in a patient population, determining the efficacy of an antihypertensive agent in achieving multiple BP targets provides additional information about the range of BP reductions attainable within this study population.
To conduct a secondary analysis of this study to evaluate the proportion of patients achieving combined SBP/DBP targets recommended in current hypertension treatment guidelines as well as individual SBP and DBP targets.
A total of 502 patients with DBP ≥100 and ≤115 mmHg were randomized to 8 weeks of treatment with placebo, HCTZ 12.5 or 25 mg/day, olmesartan medoxomil 10, 20, or 40 mg/day, or olmesartan medoxomil/HCTZ 10/12.5, 10/25, 20/12.5, 20/25, 40/12.5, or 40/25 mg/day. Mean baseline SBP ranged from 151.9 to 156.6 mmHg and mean baseline DBP ranged from 102.6 to 104.4 mmHg across the twelve treatment arms. The chi-squared test was used to compare the proportion of patients achieving each BP goal in each of the 11 active treatment regimens with that in the placebo group.
The proportion of patients achieving an SBP <140 or <130 mmHg, DBP <90, <85, or <80 mmHg and combined SBP/DBP <140/90, <130/85, <130/80, or <120/80 mmHg typically increased with escalating dosages of olmesartan medoxomil and HCTZ when administered alone or in combination, but was always highest in those treated with the combination. As the BP goal became progressively more stringent, the proportion of patients achieving the BP goal decreased in each treatment group, although the trend toward greater reductions in patients treated with combination therapy remained intact. All combined SBP/DBP goals were achieved by a statistically significant proportion of patients (p<0.05) in the olmesartan medoxomil/HCTZ 20/25, 40/12.5, and 40/25 treatment groups.
A majority of patients with uncomplicated stage 2 hypertension can achieve recommended BP goals when treated with the combination of olmesartan medoxomil and HCTZ.
- Conen, D., Ridker, P.M., Buring, J.E. (2007) Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ 335: pp. 432 CrossRef
- Lewington, S., Clarke, R., Qizilbash, N. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: pp. 1903-13 CrossRef
- Hansson, L., Zanchetti, A., Carruthers, S.G. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: pp. 1755-62 CrossRef
- Chobanian, A., Bakris, G., Black, H. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: pp. 2560-72 CrossRef
- Ong, K.L., Cheung, B.M., Man, Y.B. (2007) Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 49: pp. 69-75 CrossRef
- Materson, B.J., Reda, D.J., Cushman, W.C. (1993) Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328: pp. 914-21 CrossRef
- Messerli, F.H. (1992) Combination therapy in hypertension. J Hum Hypertens 2: pp. S19-21
- Ram, C.V. (2004) Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 6: pp. 569-77 CrossRef
- Cushman, W.C., Ford, C.E., Cutler, J.A. (2002) Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: pp. 393-404 CrossRef
- Faulkner, M.A., Hilleman, D.E. (2001) Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin Pharmacother 2: pp. 165-78 CrossRef
- Mancia, G., Backer, G., Dominiczak, A. (2007) 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25: pp. 1751-62 CrossRef
- Kochar, M., Guthrie, R., Triscari, J. (1999) Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 12: pp. 797-805 CrossRef
- Lacourciere, Y., Martin, K. (2002) Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5mg hydrochlorothiazide with 40mg telmisartan in the control of mild to moderate hypertension. Am J Ther 9: pp. 111-7 CrossRef
- McGill, J.B., Reilly, P.A. (2001) Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 23: pp. 833-50 CrossRef
- Öhman, K.P., Milon, H., Valnes, K. (2000) Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide. Blood Press 9: pp. 214-20 CrossRef
- Oparil, S., Barr, E., Elkins, M. (1996) Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 18: pp. 608-25 CrossRef
- Ruilope, L., Simpson, R., Toh, J. (1996) Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 5: pp. 32-40 CrossRef
- Sachse, A., Verboom, C.N., Jager, B. (2002) Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 16: pp. 169-76 CrossRef
- Chrysant, S.G., Weber, M.A., Wang, A.C. (2004) Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 17: pp. 252-9 CrossRef
- OLMETEC film-coated tablets. In: eMC. Surrey: Datapharm Communications Ltd, 2009 [online]. Available from URL: http://emc.medicines.org.uk/medicine/15152/SPC/OLMETEC%20film-coated%20tablets/ [Accessed 2009 Jun 18].
- Benicar® tablets [prescribing information]. Parsippany (NJ): Daiichi Sankyo, Inc. [online]. Available from URL: http://www.benicar.com/pdf/prescribing_information.pdf [Accessed 2009 Jun 18].
- Neutel, J.M., Elliott, W.J., Izzo, J.L. (2002) Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 4: pp. 325-31 CrossRef
- Sellin, L., Stegbauer, J., Laeis, P. (2005) Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 23: pp. 2083-92 CrossRef
- Gradman, A.H., Brady, W.E., Gazdick, L.P. (2002) A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100mg/hydrochlorothiazide 25mg and losartan 50mg/hydrochlorothiazide 12.5mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 24: pp. 1049-61 CrossRef
- Neutel, J.M., Franklin, S.S., Oparil, S. (2006) Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 8: pp. 850-87 CrossRef
- Fogari, R., Zoppi, A., Mugellini, A. (2006) Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 23: pp. 680-95 CrossRef
- Chrysant, S.G., Marbury, T.C., Robinson, T.D. (2003) Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 17: pp. 425-32 CrossRef
- Smith, D.H., Dubiel, R., Jones, M. (2005) Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 5: pp. 41-50 CrossRef
- Hyzaar® (losartan/HCTZ tablets) [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc. [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/h/hyzaar/hyzaar_pi.pdf [Accessed 2009 Jun 18].
- Avalide® (irbesartan-hydrochlorothiazide) [prescribing information]. Princeton (NJ): Bristol-Myers Squibb Company [online]. Available from URL: http://packageinserts.bms.com/pi/pi_avalide.pdf [Accessed 2009 Jun 18].
- Diovan HCT (valsartan and hydrochlorothiazide USP) tablets [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/diovan_hct.pdf [Accessed 2009 Jun 18].
- Oparil, S., Chrysant, S.G., Kereiakes, D. (2008) Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens 10: pp. 911-21 CrossRef
- Punzi, H.A. (2009) Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 7: pp. 229-39 CrossRef
- Izzo, J.L., Neutel, J.M., Silfani, T. (2007) Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 9: pp. 36-44 CrossRef
- Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide
American Journal of Cardiovascular Drugs
Volume 9, Issue 4 , pp 241-251
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma, School of Medicine, 5850 W. Wilshire Boulevard, Oklahoma City, Oklahoma, OK 73132, USA
- 2. Daiichi Sankyo, Inc., Parsippany, New Jersey, USA